Volitionrx Ltd VNRX

$0.24 +0.00 (0.13%)

Valuation

Market cap
3,203,000
Revenue TTM
$1,730,000
Net income TTM
$-23,360,000
PE ratio
0.00
Forward PE
—
Profit margin
-1,350.29%
Debt to equity
-0.31

Trading

Volume
1,381,500
Avg volume
10,729,354
Day's range
$0.23 – $0.24
Shares out
13,649,000
Stochastic %K
15%
Beta
1.17
Analysts
Strong Sell
Price target
$9.37

Price

Company profile

VolitionRx Limited, a multi-national epigenetics company, develops blood tests to help detect and monitor a range of cancers, and diseases associated with NETosis in the United States, Europe, and Asia. The company offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets, detects diseases associated with NETosis, such as sepsis; Nu.Q Discover, a solution to profiling nucleosomes. It also provide...

Show more

VolitionRx Limited, a multi-national epigenetics company, develops blood tests to help detect and monitor a range of cancers, and diseases associated with NETosis in the United States, Europe, and Asia. The company offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets, detects diseases associated with NETosis, such as sepsis; Nu.Q Discover, a solution to profiling nucleosomes. It also provides Nu.Q Cancer for predicting treatment response, monitoring treatment response and disease progression, and amending a patient's cancer treatment regimen; and Capture-PCR and Capture-Seq, which are isolating and capturing circulating tumor-derived DNA from plasma samples for early cancer detection. VolitionRx Limited is headquartered in Henderson, Nevada.

Industry
Medical Devices
Sector
Healthcare
Phone
512 774 8930
Website
https://volition.com
Address
1489 West Warm Springs Road, Suite 110, Henderson, United States

Latest news